Učitavanje...
Myositis and myasteniform syndrome related to pembrolizumab
This case report concerns a 63-year-old man affected by metastatic undifferentiated liposarcoma. After receiving pembrolizumab as a second-line treatment in a clinical trial, the patient experienced an immune-mediated myocarditis, myositis and myasteniform syndrome. The last two adverse events showe...
Spremljeno u:
| Izdano u: | BMJ Case Rep |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8296758/ https://ncbi.nlm.nih.gov/pubmed/34290006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2021-241766 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|